|
Adult Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this article is to provide consensus opinion from experts in the fields of hematopoietic cell transplantation, cellular immunotherapy, and lymphoma regarding key clinical questions pertinent to the use of CD19 CAR T cell products for the treatment of NHL.
|
31446199 |
2019 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The remarkable clinical response rates achieved by adoptive transfer of T cells that target CD19 in patients with leukemia and lymphoma have led to a growing number of clinical trials exploring CAR T-cell therapy for solid tumors.
|
29107016 |
2018 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In order to treat lymphoma, monoclonal antibodies (mAb) can target different antigens, including CD19, CD20 and CD22 on the surface of B-cells.
|
29922424 |
2018 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that UCB-19BBzeta and UCB-28BBzeta T cells exhibited more cytotoxicity to CD19(+) leukemia and lymphoma cell lines than UCB-19zeta and UCB-1928zeta, although differences in secretion of interleukin-2 and interferon-gamma by these T cells were not evident.
|
19719389 |
2010 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adoptive therapy using purified T(CM) cells is now the subject of a Food and Drug Administration-authorized clinical trial for the treatment of CD19(+) B-cell malignancies, and 3 clinical cell products expressing a CD19-specific CAR for IND #14645 have already been successfully generated from lymphoma patients using this manufacturing platform.
|
23090078 |
2013 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD19-CAR T cells engineered with our enhanced SB approach conferred potent reactivity in vitro and eradicated lymphoma in a xenograft model in vivo.
|
27491640 |
2017 |
|
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
By targeting CD19, a marker expressed most B-cell tumors, as well as normal B cells, CAR T-cell therapy has been investigated as a treatment strategy for B-cell leukemia and lymphoma.
|
26065479 |
2015 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effective clinical treatment with anti-CD19 CAR T cells was first reported in 2010 after a patient with advanced-stage lymphoma treated at the NCI experienced a partial remission of lymphoma and long-term eradication of normal B cells.
|
23546520 |
2013 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings define a new and novel c-Myc:CD19 regulatory loop that positively influences B cell transformation and lymphoma progression.
|
22826319 |
2012 |
|
Adult Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.
|
31439577 |
2019 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation.
|
27479233 |
2016 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this regard, CD19-specific CAR T cell therapies have achieved dramatic objective responses for a high percent of patients with CD19-positive leukemia or lymphoma.
|
30828333 |
2019 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD-19 CAR-T cells have been recently approved for high-risk R/R ALL and lymphoma.
|
29544528 |
2018 |
|
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We used T cells that were retrovirally transduced with this CAR to treat mice bearing a syngeneic lymphoma that naturally expressed the self-antigen murine CD19.
|
20631379 |
2010 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data provide evidence that CD19 plays an important role in transmitting survival and proliferation signals downstream of CD40 and therefore might be an interesting therapeutic target for the treatment of lymphoma undergoing chronic CD40 signaling.
|
24938766 |
2014 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
T cells can also be genetically modified with chimeric antigen receptors (CARs) to confer specificity for surface antigens, and studies of CD19 CARs in lymphoma also have had encouraging response rates.
|
27913506 |
2016 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two Anti-CD19 CAR-T therapies have been approved for the treatment of CD19-positive leukemia or lymphoma.
|
31429760 |
2019 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Early trials with anti-CD19 CAR T cells have achieved spectacular remissions in B-cell leukemia and lymphoma, so far refractory, very recently resulting in the Food and Drug Administration approval of CD19 CAR T cells for therapy.
|
29620951 |
2018 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The engineered CD4(+) T cells and CD8(+) T cells both exhibited specific cytotoxicity against CD19(+) leukemia and lymphoma cell lines, as well as against CD19 transfectants, and produced high-levels of antigen-dependent Th1 (but not Th2) cytokines.
|
18227839 |
2008 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.
|
30097433 |
2018 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted a clinical trial to assess the safety and efficacy of CD19-targeting CAR-T-cells in the treatment of relapsed and chemotherapy-refractory B-ALL and lymphoma.
|
30198955 |
2019 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The use of double staining with CD 5/CD 19 antibodies accompanied by two-color flow cytometric analysis clearly defined the chronic lymphocytic leukemia population and separated it from the lymphoma population.
|
2361698 |
1990 |
|
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Human CD3+CD8+ lymphocytes expressing anti-CD19 CIR mRNA inhibited Daudi lymphoma growth in NOD=SCID mice.
|
19025415 |
2009 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.
|
31690821 |
2019 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Food and Drug Administration has approved CAR T cells that target CD19 for treatment of advanced B cell leukemia and lymphoma.
|
29685162 |
2018 |